PD-L1 protein in colorectal cancer
Part of Cancer, Digestive system clinical trials.
This study looks at a protein called PD-L1 in tissue samples from people with colorectal cancer. It may help doctors understand the cancer better and guide future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Recently diagnosed with colorectal cancer (at any stage).
- You have not had colorectal surgery.
- You are a patient at South Egypt Cancer Institute or Assiut University Hospital.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of imaging scan (PD-L1 PET/CT) that may help doctors better see and understand cancers. The scan uses a special tracer to highlight cancer cells in your body, which could help guide treatment decisions.
This trial is monitoring changes in a cancer protein called PD-L1 in head and neck cancer patients before and during immunotherapy treatment. It aims to better understand how well immunotherapy will work by using regular blood tests.
This trial tests a medicine called PD-1 (a type of immunotherapy that helps your immune system fight cancer), sometimes with chemotherapy, before surgery for a certain type of colorectal cancer. It is for people whose tumors have a specific DNA repair problem (dMMR or MSI-H) and whose cancer has not spread to distant organs.
This trial tests a new therapy where immune cells (TILs) from your tumor are modified to fight cancer more effectively. It's for people with advanced colorectal cancer who can't get standard treatments.
This Phase 1 trial tests a new experimental drug (PF-08046054/SGN-PDL1V) in people with advanced solid tumors that have not responded to standard treatment or can’t use it. It is designed to see how the drug works and how safe it is, with a focus on tumors that have PD-L1 seen on prior lab testing.
This phase 3 trial studies a PD-1 antibody medicine given after surgery to help prevent stage III colon cancer from coming back. It is specifically for people whose tumor is mismatch repair–defective (dMMR) or MSI-H, which may make the cancer more responsive to immune-based treatment.
Hear when a new Colo-rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.